cytarabine has been researched along with ci 994 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Beltagi, HM; Hagenbeek, A; Martens, AC | 1 |
| Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL | 1 |
2 other study(ies) available for cytarabine and ci 994
| Article | Year |
|---|---|
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line.
Topics: Animals; Antineoplastic Agents; Benzamides; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Leukemia, Experimental; Phenylenediamines; Rats; Tumor Cells, Cultured | 2000 |
CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Cell Proliferation; Cytarabine; Daunorubicin; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Phenylenediamines; Rats; Rats, Inbred BN | 2008 |